Bank of New York Mellon’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-36,983
| Closed | -$24K | – | 4521 |
|
|
2017
Q4 | $24K | Buy |
36,983
+15,210
| +70% | +$7.68K | ﹤0.01% | 4294 |
|
|
2017
Q3 | $7K | Hold |
21,773
| – | – | ﹤0.01% | 4252 |
|
|
2017
Q2 | $10K | Sell |
21,773
-673
| -3% | -$489 | ﹤0.01% | 4269 |
|
|
2017
Q1 | $27K | Buy |
22,446
+673
| +3% | +$841 | ﹤0.01% | 4207 |
|
|
2016
Q4 | $29K | Sell |
21,773
-1,403
| -6% | -$2.44K | ﹤0.01% | 4186 |
|
|
2016
Q3 | $48K | Sell |
23,176
-4,023
| -15% | -$7.96K | ﹤0.01% | 4144 |
|
|
2016
Q2 | $44K | Hold |
27,199
| – | – | ﹤0.01% | 4195 |
|
|
2016
Q1 | $26K | Hold |
27,199
| – | – | ﹤0.01% | 4158 |
|
|
2015
Q4 | $33K | Sell |
27,199
-26,811
| -50% | -$86.1K | ﹤0.01% | 4241 |
|
|
2015
Q3 | $401K | Buy |
54,010
+6,093
| +13% | +$46.6K | ﹤0.01% | 3677 |
|
|
2015
Q2 | $342K | Sell |
47,917
-97,214
| -67% | -$757K | ﹤0.01% | 3747 |
|
|
2015
Q1 | $1.25M | Buy |
145,131
+11,553
| +9% | +$103K | ﹤0.01% | 3172 |
|
|
2014
Q4 | $1.33M | Buy |
133,578
+7,373
| +6% | +$62.9K | ﹤0.01% | 3128 |
|
|
2014
Q3 | $1.25M | Buy |
126,205
+9,409
| +8% | +$139K | ﹤0.01% | 3163 |
|
|
2014
Q2 | $2.02M | Sell |
116,796
-6,168
| -5% | -$101K | ﹤0.01% | 2894 |
|
|
2014
Q1 | $2.18M | Buy |
122,964
+1,250
| +1% | +$24.2K | ﹤0.01% | 2821 |
|
|
2013
Q4 | $2.23M | Sell |
121,714
-16,761
| -12% | -$317K | ﹤0.01% | 2821 |
|
|
2013
Q3 | $3.71M | Buy |
138,475
+38,271
| +38% | +$820K | ﹤0.01% | 2424 |
|
|
2013
Q2 | $1.85M | Buy |
+100,204
| New | +$1.77M | ﹤0.01% | 2834 |
|
Bank of New York Mellon's RPRX Position: Q1 2018 in Review
Bank of New York Mellon sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 36,983 shares — an estimated $24K sold.
Bank of New York Mellon first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $3.71M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Bank of New York Mellon reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Bank of New York Mellon sold 36,983 Repros Therapeutics Inc. shares in Q1 2018, an estimated $24K.
- Bank of New York Mellon first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Bank of New York Mellon's Repros Therapeutics Inc. position peaked at $3.71M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Bank of New York Mellon's 13F filing for Q1 2018, filed 15 May 2018.